^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
gene-modified anti-CEA T cells
i
Other names: gene-modified anti-CEA T cells, gene modified patient T cells, anti-CEA CAR-T cells, CEA CAR-T therapy, CAR2 Anti-CEA CAR-T Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roger Williams Medical Center, Sorrento
Drug class:
CEA-targeted CAR-T immunotherapy
Related drugs:
over2years
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) (clinicaltrials.gov)
P1, N=0, Withdrawn, Sorrento Therapeutics, Inc. | N=18 --> 0 | Active, not recruiting --> Withdrawn
Enrollment change • Trial withdrawal • CAR T-Cell Therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gene-modified anti-CEA T cells
over2years
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases (clinicaltrials.gov)
P2b, N=0, Withdrawn, Sorrento Therapeutics, Inc. | N=167 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • CAR T-Cell Therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • gene-modified anti-CEA T cells
3years
HITM-SURE: CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer (clinicaltrials.gov)
P1, N=5, Completed, Roger Williams Medical Center | Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Sep 2021
Trial completion • Trial completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gene-modified anti-CEA T cells
almost4years
Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors. (PubMed, Front Oncol)
In the current study, we developed a retroviral CAR construct containing a second-generation carcinoembryonic antigen (CEA)-targeting CAR with the Bcl-xL gene and tested the anti-CEA CAR-T cell immunotherapy for colorectal cancer...These results demonstrate a novel CAR-T platform that has the ability to increase the persistence of CAR-T cells in solid tumors through exogenous expression of persistent genes. The data provide a potentially novel approach to augment CAR-T immunotherapy for solid tumors.
Journal • CAR T-Cell Therapy • IO biomarker
|
BCL2L1 (BCL2-like 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gene-modified anti-CEA T cells
4years
HITM-SURE: CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer (clinicaltrials.gov)
P1, N=5, Active, not recruiting, Roger Williams Medical Center | Trial completion date: Aug 2020 --> Feb 2021
Trial completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gene-modified anti-CEA T cells
4years
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Sorrento Therapeutics, Inc. | Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Dec 2020
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
gene-modified anti-CEA T cells
Share via
